The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma

Survival in high-risk pediatric neuroblastoma has remained around 50% for the last 20 years, with immunotherapies and targeted therapies having had minimal impact. Here, we identify the small molecule CX-5461 as selectively cytotoxic to high-risk neuroblastoma and synergistic with low picomolar conc...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Min, Wright, William C., Chapple, Richard H., Zubair, Asif, Sandhu, Manbir, Batchelder, Jake E., Huddle, Brandt C., Low, Jonathan, Blankenship, Kaley B., Wang, Yingzhe, Gordon, Brittney, Archer, Payton, Brady, Samuel W., Natarajan, Sivaraman, Posgai, Matthew J., Schuetz, John, Miller, Darcie, Kalathur, Ravi, Chen, Siquan, Connelly, Jon Patrick, Babu, M. Madan, Dyer, Michael A., Pruett-Miller, Shondra M., Freeman, Burgess B., Chen, Taosheng, Godley, Lucy A., Blanchard, Scott C., Stewart, Elizabeth, Easton, John, Geeleher, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578635/
https://www.ncbi.nlm.nih.gov/pubmed/34753908
http://dx.doi.org/10.1038/s41467-021-26640-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578635/
https://www.ncbi.nlm.nih.gov/pubmed/34753908
http://dx.doi.org/10.1038/s41467-021-26640-x

Ejemplares similares